Keyphrases
Breast Cancer
100%
Tumorigenesis
100%
Drug Resistance
100%
Neratinib
100%
Breast Cancer mutations
100%
PIK3CA
50%
Human Epidermal Growth Factor Receptor 2 (HER2)
50%
Activating mutation
33%
PIK3CA mutation
33%
Palbociclib
33%
HER2 mutation
33%
Trastuzumab Deruxtecan (T-DXd)
33%
Tumor
16%
Recurrent mutation
16%
Breast Cancer Patients
16%
Patient-derived Xenograft
16%
Gene Expression
16%
RNA-seq Analysis
16%
Proteomics
16%
Breast Cancer Cells
16%
In Vitro Assay
16%
Preclinical Data
16%
Effective Strategies
16%
Tyrosine Kinase Inhibitor
16%
Human Breast Cancer
16%
Antibody-drug Conjugate
16%
Genetically Engineered Mice
16%
HER2-targeted Therapy
16%
Tumor Formation
16%
Metastatic Breast Cancer
16%
Lung Metastasis
16%
Tumor Protein p53 (TP53)
16%
Phase 1 Clinical Trial
16%
Cyclin D1 (CCND1)
16%
Drug Combination
16%
Targeting Antibodies
16%
Cyclin-dependent Kinase 4 (CDK4)
16%
P21Cip1
16%
Gene Pairs
16%
Cip1
16%
Two-drug Combination
16%
Syngeneic Mice
16%
Pan-HER
16%
Cancer Organoids
16%
CDH1
16%
Cell Cycle Markers
16%
Breast Cancer Organoid
16%
Medicine and Dentistry
Drug Resistance
100%
Carcinogenesis
100%
Breast Cancer
100%
Neratinib
60%
Organoid
20%
Combination Drug
20%
Palbociclib
20%
Trastuzumab Deruxtecan
20%
Malignant Neoplasm
10%
Neoplasm
10%
In Vitro
10%
Clinical Trial
10%
RNA Sequencing
10%
Cancer Cell
10%
Ex Vivo
10%
Transgene
10%
Cell Cycle
10%
Gene Expression
10%
Xenograft
10%
Antibody-Drug Conjugate
10%
Lung Metastasis
10%
Metastatic Breast Cancer
10%
Cyclin D1
10%
Tyrosine-Kinase Inhibitor
10%
CDK4/6 Inhibitor
10%
Proteomics
10%
Biochemistry, Genetics and Molecular Biology
Drug Resistance
100%
Carcinogenesis
100%
Neratinib
100%
Trastuzumab
33%
Transgene
16%
Gene Expression
16%
Cancer Cell
16%
Clinical Trial
16%
Cell Cycle
16%
Tyrosine Kinase Inhibitor
16%
Syngenic
16%
RNA Sequencing
16%
Genetically Engineered Mouse Strain
16%
Cyclin D1
16%
Proteomics
16%
Pharmacology, Toxicology and Pharmaceutical Science
Carcinogenesis
100%
Breast Cancer
100%
Drug Resistance
100%
Neratinib
60%
Combination Drug
20%
Palbociclib
20%
Trastuzumab Deruxtecan
20%
Neoplasm
10%
Clinical Trial
10%
Malignant Neoplasm
10%
Genetically Engineered Mouse Strain
10%
Metastatic Breast Cancer
10%
Cyclin D1
10%
Antibody Drug Conjugate
10%
Protein Tyrosine Kinase Inhibitor
10%
Lung Metastasis
10%